

## Special Issue

# Biomarkers of Neurocognitive and Psychiatric Disorders: Focusing on Transdiagnostic Approaches

### Message from the Guest Editor

Different neurocognitive and psychiatric disorders share common and distinct biomarkers. Cross-disorder analysis has revealed biomarker overlaps and differences between neurocognitive disorders (Alzheimer's disease, vascular disease, or multiple sclerosis), between psychiatric disorders (e.g., major depression, schizophrenia, or post-traumatic stress disorder), and between psychiatric and neurocognitive disorders. This Special Issue invites original research articles and reviews that use a transdiagnostic approach to extend our knowledge about overlaps and differences of biomarkers for different psychiatric and neurocognitive disorders or symptoms. Biomarkers of interest concern all levels of analysis, including the genetic, molecular, subcellular, cellular, physiological, neurofunctional, neurostructural, or behavioral level. This Special Issue aims to provide a collection of papers that advance our understanding of generic, disorder-, or symptom-overarching biomarkers on the one hand and disorder- or symptom-specific biomarkers on the other hand.

### Guest Editor

Dr. Patrick Fissler

1. Psychiatric Services Thurgau, CH-8596 Münsterlingen, Switzerland
2. University Hospital for Psychiatry and Psychotherapy, Paracelsus Medical University, A-5020 Salzburg, Austria

### Deadline for manuscript submissions

closed (29 February 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/157746](https://mdpi.com/si/157746)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).